4.5 Article

Swine flu: a Birmingham experience

期刊

CLINICAL MEDICINE
卷 9, 期 6, 页码 534-538

出版社

ROY COLL PHYS LONDON EDITORIAL OFFICE
DOI: 10.7861/clinmedicine.9-6-534

关键词

diabetes; H1N1 subtype; influenza A virus; obesity; pregnancy; swine flu

向作者/读者索取更多资源

By the beginning of July 2009 the West Midlands had seen more cases of novel H1N1 influenza (swine flu) than any other region in the UK. Over a three-week period almost 850 people presented to Heartlands Hospital with flu-like symptoms. Of those admitted 52 adults were subsequently confirmed as having H1N1 infection. Most were younger than 30 and not from traditional influenza risk groups. The main risk factor for severe disease was asthma, and to a lesser extent pregnancy and obesity. Seven patients were admitted to intensive care and five developed an acute lung injury requiring prolonged admission. Two patients required extra corporeal membrane oxygenation and one died. Despite increased workload normal clinical services were unaffected. The hospital was not closed to admissions nor was it paralysed by staff absence. With a predicted second wave expected at the end of 2009, efforts to maintain effective community assessment remain crucial.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Infectious Diseases

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial

Xinxue Liu, Alasdair P. S. Munro, Shuo Feng, Leila Janani, Parvinder K. Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Wanwisa Dejnirattisai, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L. Goodman, Christopher A. Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A. van der Klaauw, Jonathan Kwok, Vincenzo Libri, Martin J. Llewelyn, Alastair C. McGregor, Angela M. Minassian, Patrick Moore, Mehmood Mughal, Yama F. Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R. Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Teona Serafimova, Dinesh Saralaya, Gavin R. Screaton, Sunil Sharma, Ray Sheridan, Ann Sturdy, Piyada Supasa, Emma C. Thomson, Shirley Todd, Chris Twelves, Robert C. Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S. Nguyen-Van-Tam, Victoria Cornelius, Matthew D. Snape, Saul N. Faust

Summary: The decay rates of humoral response differ between vaccines 84 days after a third dose of COVID-19 vaccine. The anti-spike IgG concentrations following BNT/BNT initial doses were similar to or higher than for a three-dose BNT schedule. Half dose BNT immune responses were similar to full dose responses.

JOURNAL OF INFECTION (2022)

Article Infectious Diseases

Mapping of SARS-CoV-2 IgM and IgG in gingival crevicular fluid: Antibody dynamics and linkage to severity of COVID-19 in hospital inpatients

Samreen Ijaz, Steve Dicks, Keerthana Jegatheesan, Eleanor Parker, Ksenia Katsanovskaja, Elen Vink, Myra O. McClure, J. Shute, Joshua Hope, Nicola Cook, Peter Cherepanov, Lance Turtle, William A. Paxton, Georgios Pollakis, Antonia Ho, Peter J. M. Openshaw, J. Kenneth Baillie, Malcolm G. Semple, Richard S. Tedder

JOURNAL OF INFECTION (2022)

Article Public, Environmental & Occupational Health

Using trained dogs and organic semi-conducting sensors to identify asymptomatic and mild SARS-CoV-2 infections: an observational study

Claire Guest, Sarah Y. Dewhirst, Steve W. Lindsay, David J. Allen, Sophie Aziz, Oliver Baerenbold, John Bradley, Unnati Chabildas, Vanessa Chen-Hussey, Samuel Clifford, Luke Cottis, Jessica Dennehy, Erin Foley, Salvador A. Gezan, Tim Gibson, Courtenay K. Greaves, Immo Kleinschmidt, Sebastien Lambert, Anna Last, Steve Morant, Josephine E. A. Parker, John Pickett, Billy J. Quilty, Ann Rooney, Manil Shah, Mark Somerville, Chelci Squires, Martin Walker, James G. Logan

Summary: Sensors and trained dogs can accurately identify individuals infected with SARS-CoV-2, whether asymptomatic or with mild symptoms. Odour-based diagnostics may prove to be a rapid and effective tool for screening large numbers of people.

JOURNAL OF TRAVEL MEDICINE (2022)

Article Biochemical Research Methods

Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility

Carolina Rosadas, Maryam Khan, Eleanor Parker, Federica Marchesin, Ksenia Katsanovskaja, Macia Sureda-Vives, Natalia Fernandez, Paul Randell, Ruth Harvey, Alice Lilley, Benjamin H. L. Harris, Mohamed Zuhair, Michael Fertleman, Samreen Ijaz, Steve Dicks, Charlotte-Eve Short, Rachael Quinlan, Graham P. Taylor, Kai Hu, Paul McKay, Annachiara Rosa, Chloe Roustan, Mark Zuckerman, Kate El Bouzidi, Graham Cooke, Barnaby Flower, Maya Moshe, Paul Elliott, Alexandra J. Spencer, Teresa Lambe, Sarah C. Gilbert, Hugh Kingston, J. Kenneth Baillie, Peter J. M. Openshaw, Malcolm G. Semple, Peter Cherepanov, Myra O. McClure, Richard S. Tedder

Summary: Accurate and sensitive detection of antibody to SARS-CoV-2 is crucial in pandemic response. A double antigen binding assay (DABA) has been developed to detect and measure anti-RBD, predicting neutralising activity and vaccine response.

JOURNAL OF VIROLOGICAL METHODS (2022)

Article Infectious Diseases

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Alasdair P. S. Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K. Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L. Goodman, Christopher A. Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A. van der Klaauw, Nasir Kanji, Vincenzo Libri, Martin J. Llewelyn, Alastair C. McGregor, Mina Maallah, Angela M. Minassian, Patrick Moore, Mehmood Mughal, Yama F. Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R. Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Tanveer Bawa, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Emma C. Thomson, Shirley Todd, Chris Twelves, Robert C. Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S. Nguyen-Van-Tam, Matthew D. Snape, Xinxue Liu, Saul N. Faust

Summary: Fourth-dose COVID-19 mRNA booster vaccines are well tolerated and can enhance cellular and humoral immunity. The peak response after the fourth dose is similar to, or possibly better than, the peak response after the third dose.

LANCET INFECTIOUS DISEASES (2022)

Article Multidisciplinary Sciences

Whole-genome sequencing reveals host factors underlying critical COVID-19

Athanasios Kousathanas, Erola Pairo-Castineira, Konrad Rawlik, Alex Stuckey, Christopher A. Odhams, Susan Walker, Clark D. Russell, Tomas Malinauskas, Yang Wu, Jonathan Millar, Xia Shen, Katherine S. Elliott, Fiona Griffiths, Wilna Oosthuyzen, Kirstie Morrice, Sean Keating, Bo Wang, Daniel Rhodes, Lucija Klaric, Marie Zechner, Nick Parkinson, Afshan Siddiq, Peter Goddard, Sally Donovan, David Maslove, Alistair Nichol, Malcolm G. Semple, Tala Zainy, Fiona Maleady-Crowe, Linda Todd, Shahla Salehi, Julian Knight, Greg Elgar, Georgia Chan, Prabhu Arumugam, Christine Patch, Augusto Rendon, David Bentley, Clare Kingsley, Jack A. Kosmicki, Julie E. Horowitz, Aris Baras, Goncalo R. Abecasis, Manuel A. R. Ferreira, Anne Justice, Tooraj Mirshahi, Matthew Oetjens, Daniel J. Rader, Marylyn D. Ritchie, Anurag Verma, Tom A. Fowler, Manu Shankar-Hari, Charlotte Summers, Charles Hinds, Peter Horby, Lowell Ling, Danny McAuley, Hugh Montgomery, Peter J. M. Openshaw, Paul Elliott, Timothy Walsh, Albert Tenesa, Angie Fawkes, Lee Murphy, Kathy Rowan, Chris P. Ponting, Veronique Vitart, James F. Wilson, Jian Yang, Andrew D. Bretherick, Richard H. Scott, Sara Clohisey Hendry, Loukas Moutsianas, Andy Law, Mark J. Caulfield, J. Kenneth Baillie

Summary: This study used whole-genome sequencing to compare the genomes of 7,491 critically ill individuals with 48,400 controls, and identified 23 independent variants associated with critical COVID-19. The research found multiple genes that are involved in interferon signaling, leukocyte differentiation, and blood-type antigen secretion to be associated with critical illness.

NATURE (2022)

Article Medicine, General & Internal

Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARIC-WHO Clinical Characterisation Protocol

Marina Wainstein, Samual MacDonald, Daniel Fryer, Kyle Young, Valeria Balan, Husna Begum, Aidan Burrell, Barbara Wanjiru Citarella, Perren Cobb, Sadie Kelly, Kalynn Kennon, James Lee, Laura Merson, Srinivas Murthy, Alistair Nichol, Malcolm G. Semple, Samantha Strudwick, Steven A. Webb, Patrick Rossignol, Rolando Claure-Del Granado, Sally Shrapnel

Summary: This study found that AKI is common in patients with COVID-19 and often occurs early in the hospital admission. Using an extended KDIGO definition, more cases of AKI were identified, and these cases were associated with worse outcomes compared to patients without AKI.

PLOS MEDICINE (2022)

Article Immunology

Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19

Matthew K. Siggins, Kate Davies, Rosie Fellows, Ryan S. Thwaites, J. Kenneth Baillie, Malcolm G. Semple, Peter J. M. Openshaw, Wioleta M. Zelek, Claire L. Harris, B. Paul Morgan

Summary: This study is the largest comprehensive study of complement in COVID-19 to date. It demonstrates the important role of complement in the immunopathogenesis of COVID-19. Early-onset, uncontrolled activation of complement is a ubiquitous feature of COVID-19, further exacerbated in severe cases. These findings provide novel insights into the immunopathogenesis of COVID-19 and inform strategies for therapeutic intervention.

IMMUNOLOGY (2023)

Article Endocrinology & Metabolism

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby, Natalie Staplin, Leon Peto, Jonathan R. Emberson, Mark Campbell, Guilherme Pessoa-Amorim, Buddha Basnyat, Louise Thwaites, Rogier van Doorn, Raph L. Hamers, Jeremy Nel, John Amuasi, Manisha Rawal, Dipansu Ghosh, Jonathan Douse, Fergus Hamilton, Anthony Kerry, Pinky Thu-Ta, John Widdrington, Christopher A. Green, Purav Desai, Richard Stewart, Nguyen Thanh Phong, J. Kenneth Baillie, Maya Buch, Saul N. Faust, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Marian Knight, Wei Shen Lim, Alan Montgomery, Aparna Mukherjee, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J. Landray

Summary: Empagliflozin is not associated with reduced mortality, hospital stay, or progression to invasive mechanical ventilation or death in hospitalized adults with COVID-19.

LANCET DIABETES & ENDOCRINOLOGY (2023)

Article Infectious Diseases

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

Maheshi N. Ramasamy, Elizabeth J. Kelly, Seth Seegobin, Paul Dargan, Ruth Payne, Vincenzo Libri, Matthew Adam, Parvinder K. Aley, Nuria Martinez-Alier, Alison Church, Brett Jepson, Mark Khan, Sam Matthews, G. Todd Townsend, Johan Vekemans, Sagida Bibi, Phillip A. Swanson, Teresa Lambe, Menelas N. Pangalos, Tonya Villafana, Andrew J. Pollard, Justin A. Green

Summary: This study evaluated a variant-updated COVID-19 vaccine as a third-dose booster and compared it with the existing AZD1222 vaccine. The results showed that the vaccine had similar safety and immunogenicity to the AZD1222 vaccine, and it generated stronger immune responses.

LANCET MICROBE (2023)

Article Medicine, Research & Experimental

1 2 3 4 5678 9 10 11 12Universite de Lorraine, CHRU-Nancy, Service des Maladies Infectieuses etTropicales, Nancy, France 13U 1415 16 17 18

Bronner P. Goncalves, Waasila Jassat, Joaquin Baruch, Madiha Hashmi, Amanda Rojek, Abhishek Dasgupta, Ignacio Martin-Loeches, Luis Felipe Reyes, Chiara Piubelli, Barbara Wanjiru Citarella, Christiana Kartsonaki, Benjamin Lefevre, Jose W. Lopez Revilla, Miles Lunn, Ewen M. Harrison, Moritz U. G. Kraemer, Sally Shrapnel, Peter Horby, Zeno Bisoffi, Piero L. Olliaro, Laura Merson

Summary: Vaccinated and unvaccinated COVID-19 patients may differ in clinical presentation and comorbidities, with significant between-country variation.
Article Multidisciplinary Sciences

Liver injury in hospitalized patients with COVID-19: An International observational cohort study

Bharath Kumar Tirupakuzhi Vijayaraghavan, Saptarshi Bishnu, Joaquin Baruch, Barbara Wanjiru Citarella, Christiana Kartsonaki, Aronrag Meeyai, Zubair Mohamed, Shinichiro Ohshimo, Benjamin Lefevre, Abdulrahman Al-Fares, Jose A. Calvache, Fabio Silvio Taccone, Piero Olliaro, Laura Merson, Neill K. J. Adhikari, ISARIC Clinical Characterisation Grp

Summary: Using a large dataset, this study evaluated the prevalence and severity of liver enzyme abnormalities in COVID-19 patients and found that these abnormalities are associated with worse outcomes.

PLOS ONE (2023)

Article Medicine, General & Internal

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Peter W. Horby, Jonathan R. Emberson, Marion Mafham, Mark Campbell, Leon Peto, Guilhenne Pessoa-Amorim, Enti Spata, Natalie Staplin, Catherine Lowe, David R. Chadwick, Christopher Brightling, Richard Stewart, Paul Collini, Abdul Ashish, Christopher A. Green, Ben Prudon, Timothy Felton, Anthony Kerry, J. Kenneth Baillie, Maya H. Such, Jeremy Day, Saul N. Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Richard Haynes, Martin J. Landray

Summary: This study evaluated the use of baricitinib in the treatment of patients hospitalized with COVID-19. The results showed that baricitinib significantly reduced the risk of death, although the effect size was slightly smaller than previous trials. Overall evidence suggests that JAK inhibitors can reduce mortality in hospitalized COVID-19 patients by about 20%.

LANCET (2022)

Article Medical Informatics

Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study

Fiina Narhi, S. Ramani Moonesinghe, Susan D. Shenkin, Thomas M. Drake, Rachel H. Mulholland, Cara Donegan, Jake Dunning, Cameron J. Fairfield, Michelle Girvan, Hayley E. Hardwick, Antonia Ho, Gary Leeming, Jonathan S. Nguyen-Van-Tam, Riinu Pius, Clark D. Russell, Catherine A. Shaw, Rebecca G. Spencer, Lance Turtle, Peter J. M. Openshaw, J. Kenneth Baillie, Ewen M. Harrison, Malcolm G. Semple, Annemarie B. Docherty

Summary: The study evaluated the clinical implementation of corticosteroids in COVID-19 patients in the UK and found that patients older than 70, those with chronic neurological diseases and dementia, as well as pregnant women, were less likely to receive corticosteroids. This reflects potential inequalities in access to life-saving care among certain patient groups.

LANCET DIGITAL HEALTH (2022)

Article Respiratory System

Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study

Luis Felipe Reyes, Srinivas Murthy, Esteban Garcia-Gallo, Mike Irvine, Laura Merson, Ignacio Martin-Loeches, Jordi Rello, Fabio S. Taccone, Robert A. Fowler, Annemarie B. Docherty, Christiana Kartsonaki, Irene Aragao, Peter W. Barrett, Abigail Beane, Aidan Burrell, Matthew Pellan Cheng, Michael D. Christian, Jose Pedro Cidade, Barbara Wanjiru Citarella, Christl A. Donnelly, Susana M. Fernandes, Craig French, Rashan Haniffa, Ewen M. Harrison, Antonia Ying Wai Ho, Mark Joseph, Irfan Khan, Michelle E. Kho, Anders Benjamin Kildal, Demetrios Kutsogiannis, Francois Lamontagne, Todd C. Lee, Gianluigi Li Bassi, Jose Wagner Lopez Revilla, Catherine Marquis, Jonathan Millar, Raul Neto, Alistair Nichol, Rachael Parke, Rui Pereira, Sergio Poli, Pedro Povoa, Kollengode Ramanathan, Oleksa Rewa, Jordi Riera, Sally Shrapnel, Maria Joao Silva, Andrew Udy, Timothy Uyeki, Steve A. Webb, Evert-Jan Wils, Amanda Rojek, Piero L. Olliaro

Summary: This study investigated the clinical outcomes of severe COVID-19 patients treated outside the ICU, compared to those treated in the ICU. It found that patients admitted to an ICU had a longer hospital stay and a lower 28-day fatality ratio.

ERJ OPEN RESEARCH (2022)

暂无数据